Semiquantitative Epstein-Barr Virus (EBV) Polymerase Chain Reaction for the Determination of Patients at Risk for EBV-Induced Lymphoproliferative Disease After Stem Cell Transplantation
Open Access
- 15 May 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 91 (10) , 3654-3661
- https://doi.org/10.1182/blood.v91.10.3654
Abstract
Epstein-Barr virus–induced lymphoproliferative disease (EBV-LPD) is a serious and potentially fatal complication after allogeneic stem cell transplantation (SCT). To evaluate levels of EBV DNA in SCT patients, a semiquantitative polymerase chain reaction (PCR) assay was developed. DNA was extracted from peripheral blood leukocytes and diluted, and PCR was performed by using a primer set specific for a well-conserved sequence of the internal repeat 1 region of the EBV genome. Forty-one SCT patients were screened with this method. Thirty-seven patients received allogeneic transplants, of which 18 were T-cell–depleted marrow. Four additional patients received autologous SCT, one of which was T-cell depleted. The mean time of follow-up by EBV PCR was 147 days (range, 47 to 328 days) posttransplant. The range of EBV copies/μg DNA from normal EBV sero-positive donors was 40 to 4,000. Seven patients had ≥40,000 copies of EBV DNA/μg DNA, all of whom were recipients of T-cell–depleted SCT. Five of the seven patients with elevated levels of EBV DNA developed EBV-LPD. Four of these five patients with EBV-LPD had elevated levels of EBV DNA from 1 to 8 weeks before diagnosis. Two patients with EBV-LPD had normal levels of EBV DNA, and two patients with ≥40,000 copies EBV/μg DNA did not develop EBV-LPD. In one patient, clinical resolution of disease correlated with a decrease in EBV DNA and an increase in the level of EBV-specific cytotoxic T-cell precursors. These data indicate that the measurement of EBV viral load with semiquantitative PCR is useful in detecting EBV-LPD in high-risk patients before the onset of clinical symptoms. Because not all patients with elevated levels of EBV DNA develop EBV-LPD, semiquantitative PCR results cannot substitute for clinical, radiographic, and pathological confirmation of this diagnosis.Keywords
This publication has 39 references indexed in Scilit:
- Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferationThe Lancet, 1995
- Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignanciesBlood, 1991
- Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ TransplantationNew England Journal of Medicine, 1991
- Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow graftsBlood, 1989
- Epstein-Barr virus lymphoproliferation after bone marrow transplantationBlood, 1988
- Treatment of B-Cell Lymphoproliferative Disorders with Interferon Alfa and Intravenous Gamma GlobulinNew England Journal of Medicine, 1988
- Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantationBlood, 1988
- The Epstein-Barr Virus and The Immune SystemAdvances in Cancer Research, 1987
- Fatal Epstein-Barr-Virus-Associated Proliferation of Donor B Cells After Treatment of Acute Graft-Versus-Host Disease with a Murine Anti-T-Cell AntibodyAnnals of Internal Medicine, 1984